 |
市場調査レポート
商品コード
1452822
網膜静脈閉塞症治療の世界市場規模、シェア、成長分析：疾患タイプ別、治療法別 - 産業予測（2024～2031年）Global Retinal Vein Occlusion Treatment Market Size, Share, Growth Analysis, By Disease Type, By Treatment - Industry Forecast 2024-2031 |
||||||
| 網膜静脈閉塞症治療の世界市場規模、シェア、成長分析：疾患タイプ別、治療法別 - 産業予測（2024～2031年） |
|
出版日: 2024年03月11日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の網膜静脈閉塞症治療の市場規模は、2022年に139億2,000万米ドルとなり、2023年の154億1,000万米ドルから、2031年までには347億5,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは10.70％で成長する見通しです。
網膜静脈閉塞症（RVO）の治療市場は、RVOの有病率の上昇とこの疾患に罹患しやすい高齢者人口の拡大が要因となって、大きな成長を遂げています。一般的な網膜血管障害であるRVOは、速やかに対処しなければ視力障害や失明のリスクをもたらします。この市場では、血液循環の促進、黄斑浮腫の軽減、視力低下の予防を目的とした薬物療法、レーザー療法、外科的介入など、多様な治療オプションが提供されています。市場は治療タイプ、エンドユーザー、地域によって細分化され、中でも抗VEGF薬は血管の異常増殖と黄斑浮腫を抑制する有力な選択肢として際立っています。特に北米と欧州では、医療インフラが整備され、新しい治療法の早期導入が顕著です。アジア太平洋もまた、ヘルスケアに対する意識の高まりと医療施設の改善によって成長を遂げています。研究開発への投資拡大、診断技術の進歩、製薬会社と研究機関の協力体制といった要因が、革新的な治療法の創出を後押ししています。さらに、個別化医療や患者中心のアプローチが重視されるようになり、市場の前進が予想されます。効果的なRVO治療に対する需要が高まる中、メーカーとヘルスケアプロバイダーは、この疾患に罹患した人々の生活の質を高めることを目指し、よりアクセスしやすく効率的なソリューションを提供するために協力しています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
網膜静脈閉塞症治療の世界市場：疾患タイプ別
- 市場概要
- 網膜中心静脈閉塞症（CRVO）
- 網膜静脈分枝閉塞症（BRVO）
網膜静脈閉塞症治療の世界市場：治療法別
- 市場概要
- 抗血管内皮増殖因子（抗VEGF）
- コルチコステロイド薬
- その他
網膜静脈閉塞症治療の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Alcon
- Pfizer Inc.
- Genentech
- Regeneron Pharmaceuticals Inc.
- Allergan plc
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Sanofi
- Thrombogenics Inc.
- Acucela Inc.
- Clearside Biomedical Inc
- EyePoint Pharmaceuticals Inc.
- Sirnaomics Inc.
- Astellas Pharma Inc.
- Bellus Health Inc.
Global Retinal Vein Occlusion Treatment Market size was valued at USD 13.92 billion in 2022 and is poised to grow from USD 15.41 billion in 2023 to USD 34.75 billion by 2031, growing at a CAGR of 10.70% during the forecast period (2024-2031).
The treatment market for retinal vein occlusion (RVO) is experiencing significant growth, attributed to the rising prevalence of RVO and the expanding elderly population susceptible to this condition. RVO, a common retinal vascular disorder, poses a risk of vision impairment and blindness if not promptly addressed. This market offers diverse treatment options, including medications, laser therapy, and surgical interventions, all aimed at enhancing blood circulation, reducing macular edema, and preventing vision loss. The market is segmented based on treatment type, end-user, and region, with anti-VEGF medications standing out as a prominent choice for controlling abnormal blood vessel growth and macular edema. The market's expansion is propelled by the increasing acceptance of advanced therapies and the growing incidence of RVO cases, particularly in North America and Europe, where well-established healthcare infrastructure and early adoption of novel treatments are evident. The Asia-Pacific region is also witnessing growth, fueled by heightened healthcare awareness and improved medical facilities. Factors such as augmented investment in research and development, advancements in diagnostic techniques, and collaborative efforts among pharmaceutical companies and research institutions are fostering the creation of innovative treatment methods. Furthermore, a rising emphasis on personalized medicine and patient-centric approaches is anticipated to propel the market forward. With the demand for effective RVO treatments on the rise, manufacturers and healthcare providers are collaborating to deliver more accessible and efficient solutions, aiming to enhance the quality of life for individuals affected by this condition.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Vein Occlusion Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Retinal Vein Occlusion Treatment Market Segmental Analysis
The retinal vein occlusion treatment market is segmented on the basis of disease type, treatment, end-user, and regional. Based on Disease Type the market is segmented as, Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO). Based on Treatment the market is segmented as, Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, And Others. Based on End-user the market is segmented as, Hospital & Clinics, Research and Academics, Others. Based on Regional the market is segmented as, North America, Asia Pacific, Latin America.
Drivers of the Global Retinal Vein Occlusion Treatment Market
The growth of the retinal vein occlusion market is propelled by various factors, including the increasing global prevalence of eye diseases, a rising elderly population, enhanced comprehension of eye disorders, strengthened healthcare infrastructure, technological progress, and the introduction of novel therapies. The market's momentum is further augmented by a robust pipeline and recent approvals of new drugs. With a growing number of retinal vein occlusion cases and ongoing research into treatment molecules, the effectiveness of retinal vein occlusion therapy is witnessing an upward trend. This is supported by a strong pipeline and recent drug clearances, presenting significant opportunities for the adoption of innovative retinal vein occlusion therapeutics and contributing to the market's expansion.
Restraints in the Global Retinal Vein Occlusion Treatment Market
The bioresorbable scaffolds market encounters a hurdle due to a scarcity of extensive long-term clinical data. Additional assessment is essential to conclusively determine the efficacy and safety of bioresorbable scaffold implants in comparison to traditional stents. Evaluating the outcomes will contribute to a more comprehensive understanding of their performance over an extended period.
Market Trends of the Global Retinal Vein Occlusion Treatment Market
The rising occurrence of retinal vein occlusion, especially in the elderly demographic, is fueling the need for viable treatment solutions. With the global population aging, there is a projected increase in the prevalence of this condition, which is anticipated to contribute to the expansion of the market.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Retinal Vein Occlusion Treatment Market by Disease Type
- Market Overview
- Central Retinal Vein Occlusion (CRVO)
- Branch Retinal Vein Occlusion (BRVO)
Global Retinal Vein Occlusion Treatment Market by Treatment
- Market Overview
- Anti-vascular Endothelial Growth Factor (Anti-VEGF)
- Corticosteroid Drugs
- and Others
Global Retinal Vein Occlusion Treatment Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Alcon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thrombogenics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Acucela Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clearside Biomedical Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EyePoint Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sirnaomics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bellus Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
